Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

This trial is testing a drug called SX-682 combined with enzalutamide (a standard hormone therapy) for men with prostate cancer that has spread and stopped responding to hormone therapies. This type of cancer is called metastatic castration-resistant prostate cancer (mCRPC). **You may be eligible if...** - You are a man diagnosed with metastatic castration-resistant prostate cancer - Your cancer has progressed while on or after treatment with abiraterone, darolutamide, apalutamide, or enzalutamide - Your PSA is rising or imaging shows new/worsening tumors - Tumor tissue from a prior biopsy is available **You may NOT be eligible if...** - You have not previously received any of the above hormone therapies - You have severe heart, liver, or kidney problems - You are currently enrolled in another clinical trial - You have uncontrolled infections or other serious medical conditions Talk to your doctor to see if this trial is right for you.